RxDoctor Payments Data

Jose Guzman, MD

Cardiovascular Disease · Hollywood, FLNPI 1932155264

Payments from drug & device makers

$1,408in general payments, 2019–2025

Across 29 payments — averaging $48.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$293
  • Philips North America LLC$271
  • Boehringer Ingelheim$250
  • Merck$224
  • E.r. Squibb & Sons, L.L.C.$125
  • Heartflow, Inc.$118
  • plus $128 from 4 others

What the payments were for

  • Food & beverage$1,408100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,408 in reported general payments places this provider in the 30th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$110,662
Medicare patients
777
Services billed
1,528

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban208$210,223
EntrestoSacubitril/Valsartan120$140,839
CamzyosMavacamten13$103,164
XareltoRivaroxaban27$35,418
Repatha SureclickEvolocumab24$18,384
Metoprolol Succinate282$2,985
Olmesartan Medoxomil163$2,399
Losartan Potassium193$1,522
Nitroglycerin61$1,435
Amlodipine Besylate184$1,123
Rosuvastatin Calcium88$1,106
Carvedilol179$1,027
Ranolazine ErRanolazine14$981
Atorvastatin Calcium90$780
Omega-3 Acid Ethyl Esters11$737

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Camzyos$125$103,16413 claims
Johnson & JohnsonXarelto$30$35,41827 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Hollywood

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →